Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 7/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.50 |
| ▸ | PGR | P06401 | 1/20 | 0.50 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Paquinimod SCHEMBL29362498 | 1.00 | MEN1 (0.50) | MEN1KMT2APGRHDAC4ALDH1A1 | |
| Paquinimod SCHEMBL1573731 | 0.99 | MEN1 (0.49) | MEN1KMT2APGRHDAC4ALDH1A1 | |
| Paquinimod SCHEMBL1573653 | 0.99 | MEN1 (0.49) | MEN1KMT2APGRHDAC4ALDH1A1 | |
| Paquinimod SCHEMBL1573462 | 0.99 | MEN1 (0.49) | MEN1KMT2APGRHDAC4ALDH1A1 | |
| Paquinimod SCHEMBL1573460 | 0.99 | MEN1 (0.49) | MEN1KMT2APGRHDAC4ALDH1A1 | |
| SCHEMBL8144316 | 0.92 | MEN1 (0.47) | MEN1KMT2APGRHDAC4ALDH1A1 | |
| SCHEMBL19628902 | 0.91 | MEN1 (0.48) | MEN1KMT2APGRHDAC4ALDH1A1 | |
| SCHEMBL7537716 | 0.90 | HDAC4 (0.43) | MEN1KMT2APGRHDAC4ALDH1A1 | |
| SCHEMBL15190559 | 0.90 | MEN1 (0.51) | MEN1KMT2APGRHDAC4ALDH1A1 | |
| SCHEMBL5164257 | 0.89 | MEN1 (0.50) | MEN1KMT2APGRHDAC4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 256 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12465605-B2 | Methods and materials for gender-dependent treatment of cardiovascular dysfunction | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2025-11-11 | — | — | US | claimed |
| US-20250313900-A1 | COMPOSITIONS AND THERAPEUTIC AGENTS FOR MODULATING INFLAMMATORY RESPONSES ON BOTH TUMOR AND IMMUNE CELLS | THE METHODIST HOSPITAL | 2025-10-09 | — | — | US | claimed |
| US-20250235444-A1 | COMPOSITION FOR PREVENTING OR TREATING VALVULAR CALCIFICATION | MOKPO NATIONAL UNIVERSITY INDUSTRY-ACADEMIA COOPERATION GROUP (KR) | 2025-07-24 | — | — | US | claimed |
| CN-120136997-A | Application of S100A9 in treatment or detection of diabetic cardiomyopathy | 华中科技大学同济医学院附属同济医院 | 2025-06-13 | — | — | CN | claimed |
| WO-2025122021-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF HEART FAILURE WITH PRESERVED EJECTION FRACTION (HFPEF), THROUGH TARGETING OF S100A9 AND CORRESPONDING DIMER PARTNER AND RECEPTORS | I3S - INSTITUTO DE INVESTIGAÇÃO E INOVAÇÃO EM SAÚDE, ASSOCIAÇÃO (PT) | 2025-06-12 | — | — | WO | claimed |
| US-12318377-B2 | Method and system for reducing the likelihood of a porphyromonas gingivalis infection in a human being | SEED HEALTH, INC. (CA) | 2025-06-03 | — | — | US | claimed |
| CN-119215044-B | Application of Paquinimod in preparation of medicine for treating secondary lymphedema | 吉林大学 | 2025-03-07 | — | — | CN | claimed |
| EP-4483878-A1 | COMPOSITION FOR PREVENTING OR TREATING VALVULAR CALCIFICATION | Mokpo National University Industry-Academia Cooperation Group (KR) | 2025-01-01 | — | — | EP | claimed |
| CN-119215044-A | Application of Paquinimod in preparation of medicine for treating secondary lymphedema | 吉林大学 | 2024-12-31 | — | — | CN | claimed |
| CN-116377048-B | Application of S100A8/A9 complex in diagnosis and treatment of congenital megacolon | 广州市妇女儿童医疗中心 | 2024-05-07 | — | — | CN | claimed |
| EP-1511732-B1 | PROCESS FOR THE MANUFACTURE OF QUINOLINE DERIVATIVES | ACTIVE BIOTECH AB (SE) | 2006-12-20 | — | — | EP | claimed |
| US-20050215586-A1 | Process for the manufacture of quinoline derivatives | ACTIVE BIOTECH AB (SE) | 2005-09-29 | — | — | US | claimed |
| US-20050192315-A1 | New compositions containing quinoline compounds | ACTIVE BIOTECH AB (SE) | 2005-09-01 | — | — | US | claimed |
| US-6875869-B2 | Process for the manufacture of quinoline derivatives | ACTIVE BIOTECH AB (SE) | 2005-04-05 | — | — | US | claimed |
| US-20040034227-A1 | Process for the manufacture of quinoline derivatives | ACTIVE BIOTECH AB (SE) | 2004-02-19 | — | — | US | claimed |
| EP-1073639-B1 | QUINOLINE DERIVATIVES | ACTIVE BIOTECH AB (SE) | 2002-11-27 | — | — | EP | claimed |
| EP-1224172-A1 | DRUGS FOR THE TREATMENT OF MALIGNANT TUMOURS | Active Biotech AB (SE) | 2002-07-24 | — | — | EP | claimed |
| US-6395750-B1 | Includes laquinimod, N-ethyl-N-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxo-quinoline-3-carboxamide and its salts; breat or prostate cancer | ACTIVE BIOTECH AB (SE) | 2002-05-28 | — | — | US | claimed |
| WO-2001030758-A1 | DRUGS FOR THE TREATMENT OF MALIGNANT TUMOURS | ACTIVE BIOTECH AB (SE) | 2001-05-03 | — | — | WO | claimed |
| US-6077851-A | USED FOR TREATMENT OF DISEASES RESULTING FROM AUTOIMMUNITY SUCH AS MULTIPLE SCLEROSIS, INSULIN-DEPENDENT DIABETES MELLITUS, SYSTEMIC LUPUS ERYTHEMATOSUS, RHEUMATOID ARTHRITIS, INFAMMATORY BOWEL DISEASE AND PSORIASIS; LAQUINIMOD AS NEW CHEMICAL ENTITY | ACTIVE BIOTECH AB (SE) | 2000-06-20 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250313900-A1 | COMPOSITIONS AND THERAPEUTIC AGENTS FOR MODULATING INFLAMMATORY RESPONSES ON BOTH TUMOR AND IMMUNE CELLS | MIF, CCL2, MPEG1 | MEN1 4240/4885KMT2A 2047/4885PGR 2759/4885 |
| US-20050192315-A1 | New compositions containing quinoline compounds | KCNQ2, SCN7A, KCNQ1 | MEN1 454/4885KMT2A 424/4885PGR 4289/4885 |
| US-20250235444-A1 | COMPOSITION FOR PREVENTING OR TREATING VALVULAR CALCIFICATION | FABP3, COL2A1, ATP2A3 | MEN1 2041/4885KMT2A 3574/4885PGR 4331/4885 |
| US-20040034227-A1 | Process for the manufacture of quinoline derivatives | CYP4F3, HTR3C, CYP3A43 | MEN1 2749/4885KMT2A 2359/4885PGR 2087/4885 |
| US-20050215586-A1 | Process for the manufacture of quinoline derivatives | ADH5, RPS4Y1, CYP4F3 | MEN1 2560/4885KMT2A 2223/4885PGR 1403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.